Publication | Closed Access
Treatment choice of immunotherapy or further chemotherapy for Epstein–Barr virus‐associated hemophagocytic lymphohistiocytosis
37
Citations
33
References
2011
Year
No cytotoxic agents were needed for >60% of EBV-HLH patients. Early immunotherapy may modulate T-cell activation and reduce the chance of unnecessary chemotherapy.
| Year | Citations | |
|---|---|---|
Page 1
Page 1